FDA’s Discovery Of Heparin Contaminant Underscores Risks Manufacturers Face
This article was originally published in The Pink Sheet Daily
Executive Summary
Fatal contaminant went undetected because it mimicked actual heparin in conventional assays .
You may also be interested in...
Baxter Heparin Case Highlights Global Supply Chain Vulnerabilities
Correct paperwork no guarantee even legitimate API manufacturers operate according to Chinese govt. standards, chemical exec says.
U.S. FDA Inspected “Wrong” Heparin API Manufacturer – Compliance Official
Baxter heparin scare benefits American Pharmaceutical Partners, the other supplier of heparin to the U.S. market.
Baxter Suspends Multiple-Dose Heparin Manufacturing Due To Excess Adverse Events
Firm avoids FDA recall; continues to manufacture single-dose vials of blood thinner.